Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Premature infants frequently have trouble breathing after birth. If the respiratory disorder
is caused by surfactant deficiency or dysfunction, the disease is treated with a medication
called surfactant that is given to the infant through a tube inserted into the windpipe. This
study will compare the safety of two of the commonly used surfactants, poractant and
calfactant,in the United States. Poractant has added chemicals called phospholipids which are
known to cause inflammation and irritation in the body of premature infants. The
investigators will compare this to another similar surfactant that does not contain these
chemicals by looking at samples from the windpipe, while the tube is in place, and from blood
tests in the first few days of life.
The investigators are hoping to learn whether calfactant is a safer therapeutic agent to
treat respiratory distress syndrome in preterm infants compared to poractant.